JHVEPhoto/iStock Editorial via Getty Images The European Commission has fined Israeli drugmaker Teva Pharmaceutical Industries ( NYSE: TEVA ) EUR 462.6M, or around $500M, for trying to ward off competition for its blockbuster multiple sclerosis drug Copaxone in Europe by disparaging a rival product. The commission found that.
